Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer

Inclusion Criteria: * Histologically proven dx of recurrent or metastatic breast cancer * Must have received at least 1 but not more than 3 prior chemotherapy regimens for recurrent or metastatic breast cancer. Patients who relapse within 12 months of completing adjuvant chemotherapy can only have had up to 2 prior regimens for metastatic disease. Patients who relapse within 12 months of completing adjuvant chemotherapy containing an anthracycline and a taxane, do not require prior chemotherapy for metastatic disease. * Unidimensionally measurable dz (by RECIST) * At least 18 yrs of age * SWOG PS 0-2 * AGC greater than or equal to 1.5; platelets greater than or equal to 100,000; Hgb greater than or equal to 8.0 * Total bilirubin less than or equal to 2 x uln; SGOT and/or SGPT and alk phos up to 2.5 x uln * Creatinine less than or equal to 2.0 * Fully recovered from acute toxicities secondary to prior tx * Signed informed consent (including HIPAA authorization) * Peripheral neuropathy grade 0-1 Exclusion Criteria * Prior tx with gemcitabine or oxaliplatin. Prior tx with cisplatin or carboplatin allowed if completed \>12 mos prior to enrollment. * Underlying medical, psychiatric, or social conditions that would preclude patient from receiving tx * Peripheral neuropathy greater than or equal to Gr 2 Exclusion Criteria: \-